company background image
NKTX logo

Nkarta NasdaqGS:NKTX Stock Report

Last Price

US$6.01

Market Cap

US$439.0m

7D

-8.9%

1Y

23.4%

Updated

14 Jun, 2024

Data

Company Financials +

NKTX Stock Overview

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

NKTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Nkarta, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nkarta
Historical stock prices
Current Share PriceUS$6.01
52 Week HighUS$16.24
52 Week LowUS$1.28
Beta0.88
1 Month Change-12.65%
3 Month Change-50.60%
1 Year Change23.41%
3 Year Change-77.30%
5 Year Changen/a
Change since IPO-87.45%

Recent News & Updates

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

May 23

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27

Recent updates

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

May 23

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25

Nkarta: Possible Upside From H1 Update, If Positive

Jan 25

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Jan 16
Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Oct 04
We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Jun 21
We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Mar 06
We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09
We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23
We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25
We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Shareholder Returns

NKTXUS BiotechsUS Market
7D-8.9%0.02%1.2%
1Y23.4%6.7%20.6%

Return vs Industry: NKTX exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: NKTX exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is NKTX's price volatile compared to industry and market?
NKTX volatility
NKTX Average Weekly Movement14.4%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: NKTX's share price has been volatile over the past 3 months.

Volatility Over Time: NKTX's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015150Paul Hastingswww.nkartatx.com

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.

Nkarta, Inc. Fundamentals Summary

How do Nkarta's earnings and revenue compare to its market cap?
NKTX fundamental statistics
Market capUS$439.01m
Earnings (TTM)-US$116.20m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$116.20m
Earnings-US$116.20m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.65
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NKTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.